Andre H Goy MDChairman & Executive Director and Lymphoma Division Chief, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey
Andre Goy, MD, is Chairman and Director of John Theurer Cancer Center (JTCC) at Hackensack Meridian Health, Hackensack University Medical Center, a member of the National Cancer Institute (NCI)-designated Lombardi Comprehensive Cancer Center Consortium. JTCC provides the largest oncology program in New Jersey and is also a member of the Memorial Sloan Kettering-Hackensack Meridian Health partnership. Dr. Goy is also Professor and Founding Chair of the Department of Oncology at the Hackensack Meridian School of Medicine at Seton Hall University, as well as Professor of Medicine at Georgetown University in Washington, DC.
Dr. Goy is widely known for his work in lymphoma, particularly in drug development in mantle cell lymphoma and other aggressive lymphomas. His research interest also includes the identification of prognostic markers and better ways to stratify patients with lymphoma. Dr. Goy has served on the steering committee for the NCI for lymphoma and on the scientific advisory board of the Lymphoma Research Foundation. Dr. Goy and his team are exploring new forms of immunotherapy and cell therapy post transplantation, particularly using checkpoint inhibitors, taking advantage of the favorable milieu during immune reconstitution post stem cell transplantation. Dr. Goy has been involved in the development of CAR-T cell therapy at Hackensack University Medical Center with the NCI for almost a decade, which led to the first approval of CAR-T cells in lymphoma in November 2017.
Dr. Goy believes that a true revolution is happening in cancer medicine, which will be driven by cell-based therapies/immunotherapy, precision medicine, analytics, and connectivity. The bioinformatics platform developed at JTCC – called COTA – uses a unique classification system compressing all relevant individual patient data into a usable code (CNA). This digital architecture allows us to reduce adverse variance, optimize decisions in cancer care, and improve outcome at the individual level, while lowering costs for the population along the way and supporting value-based care initiatives.
Dr. Goy has published more than 180 peer reviewed papers and serves as reviewer for many journals in the field, including the New England Journal of Medicine, the Journal of Clinical Oncology, Blood, and the American Society of Hematology Journal, among others. He has been the co-chair of the Global Council on the Future of Health and Healthcare for the World Economic Forum since 2015. He believes that we are at an inflection point in medicine due to unprecedented combination of rapid progress in science and discovery, but also technology, which will help reshape both health and healthcare delivery.
Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France, before completing his training in hematology oncology in Paris at the Faculté of Medicine Cochin Port Royal. While there, he also received a master’s degree in tumor immunology from Pasteur Institute and Curie University Paris VI as well as a master’s degree in experimental oncology from University Kremlin Bicetre. Dr. Goy was on faculty at Memorial Sloan-Kettering and M.D. Anderson Cancer Center before joining John Theurer Cancer Center in 2005. Dr. Goy now serves as Chair of Oncology for Hackensack Meridian Health, the largest, most comprehensive and truly integrated health care network in New Jersey, with 17 hospitals from Bergen to Ocean counties.
DisclosuresDr. Andre Goy discloses the follwoing:
- Consultant for Kite/Gilead, Janssen, Celgene, Acerta, Astrazenca
- Equity ownership in COTA
- Research funding from Acerta, AstraZeneca, Genentech, Hakensackumc, Pharmacyclics and University of Nebraska -through clinical trials for institution
- Honoraria from Kite/Gilead, Janssen, Celgene, Acerta, Astrazenca
- Board of Directors/Advisory Committees for Kite/Gilead, Janssen, Celgene, Acerta, Astrazenca, COTA
Recent Contributions to PracticeUpdate:
- ASCO 2019: Abstract Recommendations From Dr. Andre Goy for Lymphoma
- Rituximab Plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- Critical Management Scenarios: Large Cell Lymphoma Beyond R-CHOP and High Risk Follicular Lymphoma Patients
- Hematology Practice Implications: New Hodgkin's Lymphoma Research
- Hematology Practice Implications: New Large Cell Lymphoma Research
- Hematology Practice Implications: New Adult T-Cell Lymphoma Research
- Hematology Practice Implications From ASCO: Chronic Lymphocytic Leukemia
- Dr. Andre Goy's 2014 ASCO Abstract Recommendations—Lymphoma
- Dr. Andre Goy's 2013 ASH Abstract Recommendations: Lymphoma
- This Week Ibrutinib Became the First-in-Class Drug Targeting the B-Cell Receptor Pathway